Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status by Babapour Mofrad, Rosha et al.
RESEARCH Open Access
Plasma amyloid-β oligomerization assay as
a pre-screening test for amyloid status
Rosha Babapour Mofrad1,2* , Philip Scheltens2, SangYun Kim3, Sungmin Kang4, Young Chul Youn5,
Seong Soo A. An6, Jori Tomassen2, Bart N. M. van Berckel7, Pieter Jelle Visser2,8, Wiesje M. van der Flier2,9 and
Charlotte E. Teunissen1
Abstract
Objective: We assessed the performance of plasma amyloid oligomerization tendency (OAβ) as a marker for
abnormal amyloid status. Additionally, we examined long-term storage effects on plasma OAβ.
Methods: We included 399 subjects regardless of clinical diagnosis from the Amsterdam Dementia Cohort and
European Medical Information Framework for AD project (age, 63.8 ± 6.6; 44% female). Amyloid status was
determined by visual read on positron emission tomography (PET; nabnormal = 206). Plasma OAβ was measured
using the multimer detection system (MDS). Long-term storage effects on MDS-OAβ were assessed using general
linear models. Associations between plasma MDS-OAβ and Aβ-PET status were assessed using logistic regression
and receiver operating characteristics analyses. Correlations between plasma MDS-OAβ and CSF biomarker levels
were evaluated using Pearson correlation analyses.
Results: MDS-OAβ was higher in individuals with abnormal amyloid, and it identified abnormal Aβ-PET with an
area under the curve (AUC) of 0.74 (95% CI, 0.67–0.81), especially in samples with a storage duration < 4 years.
Combining APOEe4 and age with plasma MDS-OAβ revealed an AUC of 81% for abnormal amyloid PET status (95%
CI, 74–87%). Plasma MDS-OAβ correlated negatively with MMSE (r = − 0.29, p < .01) and CSF Aβ42 (r = − 0.20, p <
0.05) and positively with CSF Tau (r = 0.20, p = 0.01).
Conclusions: Plasma MDS-OAβ combined with APOEe4 and age accurately identifies brain amyloidosis in a large
Aβ-confirmed population. Using plasma MDS-OAβ as a screener reduced the costs and number of PET scans
needed to screen for amyloidosis, which is relevant for clinical trials. Additionally, plasma MDS-OAβ levels appeared
affected by long-term storage duration, which could be of interest for others measuring plasma Aβ biomarkers.
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Background
Accumulating evidence shows that small soluble
Amyloid-β oligomers (AβOs) are the most toxic and
pathogenic form of Aβ species in Alzheimer’s disease
(AD) [1, 2]. Many toxicities have been ascribed to AβOs
including synaptic dysfunction, induction of tau path-
ology, neuroinflammation, impaired axonal transport,
and neuronal death [3]. In addition, AβOs have shown a
better correlation with the presence and degree of cogni-
tive symptoms than Aβ plaque counts [4], suggesting
that AβOs might provide a more accurate reflection of
clinical presentation than Aβ plaque load.
Currently, proxies of Aβ plaques are measured with
high sensitivity and specificity with positron emission
tomography (PET) imaging or measurement of cerebro-
spinal fluid (CSF) Aβ42 concentrations. However, these
methods often come with high costs or burden for the
patient. Therefore, blood-based biomarkers are consid-
ered low-cost and minimally invasive alternatives.
Plasma AβO concentrations or misfolded Aβ oligo-
meric assemblies have previously shown good diagnostic
accuracies in identifying AD from controls (area under
the curve (AUC), 0.71–0.80) [5, 6]. Using the multimer
detection system (MDS) to measure plasma AβO levels
has resulted in even higher diagnostic accuracies (AUC,
0.85–0.87) in discriminating AD dementia patients from
controls [7]. However, the ability of plasma amyloid
oligomerization tendency measured by the multimer de-
tection platform (MDS-OAβ) to identify individuals with
abnormal amyloid status has not yet been studied. This
is relevant, because the definition of AD in vivo is shift-
ing to a biological construct and increasingly based on
amyloid status [8]. Therefore, we aimed to assess the




We included 399 subjects from the Amsterdam Demen-
tia Cohort (ADC) and the European Information Frame-
work for AD (EMIF-AD) Preclinical AD project,
regardless of clinical diagnosis. Inclusion criteria were
met when amyloid PET results were available and the
time between plasma sampling and PET scan did not ex-
ceed 1 year. During their visit, all subjects underwent
comprehensive dementia screening including neurologic
examination, laboratory tests, magnetic resonance im-
aging (MRI), and electroencephalography (EEG) [9, 10].
Clinical diagnosis was established by consensus accord-
ing to international consensus criteria [8, 11–14], and
included mild cognitive impairment (MCI; n = 42), AD
dementia (n = 164), non-AD dementia (n = 58), and
other disorders (n = 61) including neuropsychiatric dis-
orders, neurological disorders, or individuals with
postponed diagnosis. Controls consisted of participants
with subjective cognitive decline (SCD; n = 14) and nor-
mal controls (NC; n = 60). Normal controls in this study
were included from the preclinical AD study [15]. No
known familial AD patients were included. CSF and PET
results (below) were used to support the AD dementia
diagnosis and to define the number of amyloid-positive
subjects within each clinical diagnostic group.
Amyloid status
Amyloid PET status was available in all subjects (n = 399).
[18F]Florbetaben (n = 138), [18F]florbetapir (n = 1), [18F]flu-
temetamol (n = 138), or [11C]Pittsburgh compound B (PiB;
n = 122) were used as radioactive amyloid tracers. A Medrad
(Warrendale, PA) infusion system was used for tracer infu-
sion. [18F]Florbetapir and [11C]PIB scans were acquired
through 90-min dynamic scanning using a PET/CT Ingenu-
ity TF or Gemini TF [Philips Medical Systems, Best, the
Netherlands] ([18F]Florbetapir), and ECAT EXACT HR +
scanner [Siemens/CTI, Knoxville, TN] ([11C]PIB). Scanning
started simultaneously with tracer infusion at approximately
370 MBq [18F]florbetapir and 351 MBq [11C]PiB. [18F]Flor-
betaben and [18F]flutemetamol scans were acquired through
20-min static PET scanning using a PET/MR and Gemini
TF-64 PET/CT scanner, Philips Medical Systems, respect-
ively. Scanning started 90 min after tracer injection at ap-
proximately 250 MBq [18F]florbetaben and 180 MBq
[18F]flutemetamol. Amyloid status was defined as either ab-
normal or normal after visual assessment by either one
(ADC) or three experienced nuclear medicine physicians
(preclinical AD project) where majority vote ruled.
Cerebrospinal fluid analysis
CSF Aβ42 was measured using two analytical methods:
Innotest and Euroimmun ELISAs. Innotest ELISAs were
used to measure levels of CSF amyloid beta 1-42, total
Tau (Tau) and Tau phosphorylated at threonine 181
(pTau) for 268 subjects (Fuijirebio, Ghent, Belgium).
CSF Aβ levels were corrected for the drift seen through-
out CSF analysis years [16]. Euroimmun beta-amyloid
ELISAs (Euroimmun, Lübeck, Germany/ADx Neurosci-
ences, Ghent, Belgium) were used to measure levels of
CSF Aβ1-40 and 1-42 of normal controls (n = 60). All
CSF samples were measured centrally at the Neuro-
chemistry Laboratory of Amsterdam UMC.
Apolipoprotein E status
APOE genotyping was performed using LightCycler
ApoE mutation Detection Kit (Roche Diagnostics,
GmbH, Mannheim, Germany), after isolation of genomic
DNA from ethylenediaminetetraacetic acid (EDTA)
plasma (Qiagen, Venlo, the Netherlands). APOEe4 status
was dichotomized into APOEe4 allele carriers (i.e., at
Babapour Mofrad et al. Alzheimer's Research & Therapy          (2021) 13:133 Page 2 of 10
least one APOEe4 allele) and non-carriers (i.e., no
APOEe4 allele).
Plasma sampling and analysis
Blood plasma was collected in an EDTA vacutainer tube
through venipuncture using standardized in-house pro-
tocols. EDTA plasma was centrifuged at 1800×g for 10
min at room temperature and stored in 0.5 ml polypro-
pylene tubes at – 80 °C in the Amsterdam UMC bio-
bank. Prior to analysis, plasma aliquots were thawed at
37 °C for 15 min. Peoplebio Inc. measured MDS-OAβ
levels in all plasma samples centrally using the multimer
detection system, which is CE marked, approved by the
Korean FDA and under commercialization for the Asian
and European markets. The assay essentially is an ELISA
assay, with the exception that samples and standards
were mixed with a proprietary amyloid beta protein mix-
ture before starting the sandwich procedure. Results are
expressed as ratio of the concentration calculated in the
standard curve for each sample over the average results
obtained for two internal standards. All samples were
analyzed twice in singlet, on 2 consecutive days. Intra-
assay variations were below 10% and 2% of the samples
(n = 8) showed interassay variations higher than 20% co-
efficient of variation (CV) (these samples were included
in the analyses). All samples were above the lower limit
of quantification (LLOQ; 0.239 ng/ml). Hemolytic sam-
ples (n = 15) were excluded, as hemoglobin might inter-
fere with the MDS-OAβ signal [17]. The exact MDS
method was described in detail previously [18]. The re-
producibility of MDS-OAβ test confirmed by testing the
control materials with four concentrations (highly con-
centrated positive, medium concentrated positive, low
concentrated positive and negative) with three different
LOTs, two different instruments/site, three different tes-
ters for 5 days with five replicate per each sample. As a
result, all 225 positive sample test results were positive
and all 75 negative sample test results were negative,
showing 100% reproducibility, and calculated CV% of
MDS ratio for total and between LOT, tester, and instru-
ment (site) was approximately 5%. There was no inter-
ference of albumin, hemoglobin, or biliburin, nor cross
reactivity of Mutant Aβ1-42 monomer peptide, Aβ4-42
peptide, Aβ9-42 peptide, and Aβ1-24 peptide with a
concentration of 1.25 ng/ml.
Statistical analyses
SPSS version 24 (IBM, Armonk, NY) was used for all stat-
istical analyses, and data were visualized using R version
3.5.2 (“eggshell igloo”). Subject characteristics were com-
pared between amyloid normal and abnormal subjects,
using Student’s t-test, chi-squared test, and Mann-
Whitney U tests where appropriate. Plasma MDS-OAβ
was normalized using a 2-step transformation [19]. Upon
visual inspection, we recently observed a possible effect of
long-term storage on plasma MDS-OAβ levels (data not
published). As plasma samples which are used for research
purposes might have a long storage period after biobank
retrieval, we additionally assessed the effect of long-term
storage on plasma MDS-OAβ levels by using general lin-
ear models (GLM) with factors sample storage period,
PET amyloid status, and their 2-way interactions. In case
of a significant 2-way interaction between storage period
in years and PET amyloid status, we performed GLM for
plasma MDS-OAβ stratified for storage period based on
the median storage period (4 years). Differential expres-
sion of plasma MDS-OAβ levels between normal amyloid
and abnormal amyloid subjects was evaluated using GLM
with plasma MDS-OAβ as outcome measure, amyloid sta-
tus as factor, and age, sex, APOEe4 status, and cohort as
covariates. Syndrome diagnosis was not a confounder and
therefore not included as a covariate. Pearson correlation
analyses were used to assess correlations between plasma
MDS-OAβ and Mini Mental State Examination (MMSE)
scores as measure of global cognition, or levels of CSF
Aβ42, Tau, and pTau measured by Innotest ELISA. The
potential of the plasma Aβ oligomer assay to identify PET
abnormal amyloid status was assessed by receiver operat-
ing characteristic (ROC) analysis using predicted values of
binary logistic regression models. The area under the
curve (AUC) and corresponding sensitivities and specific-
ities were calculated at an optimal cut-off for each model
using Youden J’s index (sensitivity + specificity − 1). The
models contained (1) plasma MDS-OAβ, (2) age and
APOEe4 status, or (3) plasma MDS-OAβ combined with
age and APOEe4 status. AUC’s between models were
compared using DeLong analysis [20]. Additionally, to as-
sess the performance of the plasma MDS-OAβ assay in
early AD stages, analyses were repeated in a subgroup of
pre-dementia subjects including controls and MCI sub-
jects. Lastly, we investigated how the use of the plasma
MDS-OAβ marker can reduce the costs and number of
PET scans needed to screen individuals for a hypothetical
clinical trial which needs 100 abnormal amyloid individ-
uals. For this analysis, we used the sensitivity and specifi-
city levels that corresponded with the highest Youden cut-
off. Analyses were stratified for SCD, MCI, and AD de-
mentia diagnosis as the prevalence of abnormal amyloid
individuals differs per diagnosis [21]. We assumed an
average cost of 5000 USD [22] per amyloid PET scan and
estimated 100 USD per plasma MDS-OAβ sample. A p-
value < 0.05 was considered statistically significant.
Results
Patient characteristics
The average age of the total population was 63.8 ± 6.6
years old, 44% was female, and the average MMSE was
24 ± 5. Abnormal amyloid status was found in 206
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(52%) subjects which included more often AD dementia
subjects, whereas normal amyloid subjects included
more often controls. Individuals with abnormal amyloid
had lower MMSE scores and were more often APOEe4
carrier compared to individuals with normal amyloid
status (Table 1). An interaction with storage period was
found (p < 0.01; Fig. 1, Table 2), after which the cohort
was stratified based on the median storage period (4
years). The groups with storage period ≤ 4 years and > 4
years did not differ from each other in patient character-
istics. Both had more abnormal amyloid subjects who
had lower MMSE scores and were more often APOEe4
carrier than amyloid normal subjects (Table 1).
Plasma MDS-OAβ performance in samples with a storage
duration < 4 years
For samples with a storage period ≤ 4 years (n = 207),
plasma MDS-OAβ levels corrected for age, sex, APOEe4
status, and cohort were higher in abnormal amyloid sub-
jects compared to normal amyloid subjects (β ± se, 0.17 ±
0.05; p = 0.001; Fig. 1). Plasma MDS-OAβ was negatively
correlated with CSF Aβ42 levels (r = − 0.20, p = 0.035)
and MMSE scores (r = − 0.29, p < 0.01) and positively cor-
related with CSF Tau (r = 0.20, p = 0.01) (Fig. 2). There
was no correlation with CSF pTau levels (r = 0.12,
p>0.05). ROC analyses (Fig. 3) revealed that plasma MDS-
OAβ could accurately identify individuals with abnormal
amyloid PET (AUC = 0.74, 95% CI = 0.67–0.81), with a
sensitivity of 76% and specificity of 67%. When combined
with age and APOEe4 status the AUC increased to 0.81
(95% CI = 0.74–0.87), with a sensitivity and specificity of
58% and 89%, which performed better than age and
APOEe4 genotype alone (AUC = 0.70, 95% CI = 0.63–
0.78, p = 0.01).
Plasma MDS-OAβ performance in samples with a long-
term storage duration
We repeated our analyses in samples (n = 192) that had
been stored for a longer period (> 4 years) and observed
no difference in plasma MDS-OAβ levels between abnor-
mal and normal amyloid individuals (β ± se, 0.04 ± 0.06, p
> 0.05, Fig. 2) nor could it discriminate between abnormal
and normal amyloid status (AUC, 0.50, p > 0.05).
Plasma MDS-OAβ as an early predictor of amyloid status
and syndrome diagnosis
Next, analyses were repeated in a pre-dementia sub-
group including CN and MCI subjects (storage period ≤
4 years; n = 78). Plasma MDS-OAβ could identify indi-
viduals with abnormal amyloid PET with an AUC of
0.77 (95% CI = 0.60–0.93), and a sensitivity and specifi-
city of 67% and 83%, respectively. When combined with
age and APOEe4 status the AUC increased to 0.86 (95%
CI = 0.75–0.96), with a sensitivity and specificity of 75%
and 83%, which performed better than age and APOEe4
Table 1 Subject characteristics
Total cohort Sample storage period (≤ 4 years) Sample storage period (> 4 years)













Age, year 64.4 (6.5) 63.2 (6.6) 64.6 (6.2) 63.2 (6.5) 64.0 (7.3) 63.2 (6.7)
Female sex, n % 75 (39) 101 (49)* 54 (39) 34 (50) 21 (39) 67 (49)
MMSE (n = 393) 26 (4) 22 (5)*** 27 (3.9) 22 (4.7)*** 25 (3.7) 22 (4.6)***
Education, year (n = 334) 10.7 (2.9) 11.4 (2.9)* 10.5 (2.9) 11.0 (2.6) 10.9 (3.0) 11.7 (3.0)
Diagnosis
CNb/MCI/AD/ 70/15/11/ 4/27/153/*** 63/4/6/ 2/10/44/*** 7/11/5/ 2/17/109/***
Non-AD/Other 49/48 9/13 30/36 3/9 19/12 6/4
APOE ε4 carrier (n = 389) 59 (30%) 140 (70%)*** 42 (31%) 46 (69%)*** 17 (32%) 94 (72%)***
CSF aβ42 (pg/ml)
Innotest (n = 268) 1033 (246) 629 (131)*** 1036 (284) 610 (182)*** 1027 (184) 638 (102)***
Euroimmun (n = 60) 999 (309) NA 999 (309) NA 999 (309) NA
Plasma MDS-OAβ assaya 0.80 (0.33) 0.97 (0.35)*** 0.76 (0.32) 1.03 (0.28)*** 0.89 (0.35) 0.95 (0.37)
* p<0.05, ** p<0.01, *** p<0.001
aHemolytic samples excluded
bControls include normal controls and SCD subjects
Non-AD dementia patients include possible AD, FTD, DLB, VaD and CBD, and PSP. Other includes psychiatry, other neurological diseases, postponed diagnosis or
PPA. Data are presented as mean (SD) unless otherwise specified. Independent t-test or chi-squared test was performed where appropriate
Abbreviations: NA not available, MMSE Mini Mental State Examination, MCI mild cognitive impairment, FTD frontotemporal dementia, DLB dementia with Lewy
Bodies, VaD vascular dementia, PPA primary progressive aphasia, AD Alzheimer’s disease dementia, non-AD non-Alzheimer’s disease dementia, aβ42 amyloid-β1-
42, MDS-OAβ Aβ oligomerization tendency, PET positron emission tomography
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genotype on a trend level (AUC, 0.76; 95% CI, 0.62–
0.89, p = 0.10).
We next performed an exploratory analysis of the
prediction of amyloid positivity in the non-AD and
other diagnosis subgroups. The data showed largely
similar results. For the comparison of abnormal amyl-
oid PET vs normal amyloid PET, we observed an
AUC of 0.72 in non-AD subgroup and an AUC of
0.75 in the other diagnosis subgroup, controlled for
age and APOEe4 status.
Exploratory cost-evaluation for plasma MDS-OAβ as a
pre-screener
Lastly, we explored how the use of plasma oligomers as
a pre-screen could reduce costs to find 100 individuals
with amyloid pathology on a PET scan in the total group
of individuals with normal cognition, MCI, or AD de-
mentia. Given an expected prevalence of amyloid path-
ology of 30% in CN, 50% in MCI, and 70% in AD
dementia subjects [21], the number of amyloid PET
scans to find 100 amyloid positives within each group
without pre-screening would be 333 (CN), 200 (MCI),
and 143 (dementia). Assuming the sensitivity of 76% and
specificity of 67% of the plasma MDS-OAβ test (highest
Youden cut-off, 0.45) in this total cohort, MDS-OAβ
needed to be determined in 439 CN, 263 MCI, and 188
AD dementia subjects to identify 195 CN, 141 MCI, and
118 AD dementia subjects with an abnormal MDS-OAβ
test in order to find 100 abnormal amyloid PET cases
Fig. 1 Scatterplot presents the correlation between plasma MDS-OAβ and storage period in years. Blue dots represent normal amyloid PET individuals,
and red dots represent abnormal amyloid PET individuals
Table 2 Full model for storage period and amyloid PET status
for plasma MDS-OAβ
β (se)b p-value
Storage period, yrs .03 (.01) .02
Amyloid PET statusa .38 (.08) < .001
Amyloid PET status × storage period, yrs − .04 (.01) .003
We used general linear models (GLM) with factors storage period and PET
amyloid status, and their 2-way interactions
aReference is normal amyloid PET status. p < 0.05 is considered significant
bPlasma MDS-OAβ was normalized using two-step transformation
MDS-OAβ Aβ oligomeric tendency, yrs years, PET positron
emission tomography
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within each clinical group. The plasma MDS-OAβ assay
as a pre-screener for amyloid PET analysis would thus
reduce the number of PET scans with 138 (40%) in CN,
59 (30%) in MCI, and 25 (18%) in AD dementia subjects.
Considering the costs for a PET analyses and MDS-OAβ
only, this would result in a cost reduction of 40% in CN,
30% in MCI, and 15% in AD dementia based on these
figures.
Discussion
We showed that plasma MDS-OAβ has good accuracy
to pre-screen for brain amyloidosis in a memory clinic
population, particularly when combined with APOEe4
and age (AUC > 0.80). In addition, plasma MDS-OAβ
showed a negative correlation with CSF Aβ42 and
MMSE, and a positive correlation with CSF Tau. Using
plasma MDS-OAβ as a pre-screener resulted in reduced
number of PET scans and lowered costs for amyloid
screening up to 40%, which is highly beneficial for clin-
ical trials. Of note, these results are only valid for rela-
tively fresh samples, as a negative effect of long-term
storage was found for plasma MDS-OAβ concentrations.
To date, few studies have measured Aβ oligomers
levels in blood plasma, as detecting crude oligomeric Aβ
in plasma is challenging owing to its low concentration
in blood. Using the MDS platform, we successfully mea-
sured increased plasma MDS-OAβ levels in abnormal
amyloid PET individuals compared to individuals with
normal amyloid PET levels. This finding is in line with
previous studies reporting increased levels of Aβ oligo-
mers in brain tissue, CSF, and plasma of AD patients [5,
23–25]. This increase in Aβ oligomer levels is in contrast
to monomeric Aβ levels, which show an evident de-
crease rather than increase in blood plasma [26–30].
This upregulation of Aβ oligomers could be explained
by oligomerization of Aβ monomers, resulting in higher
plasma Aβ oligomer levels and decreased monomeric Aβ
levels. Our results also showed a correlation between
plasma MDS-OAβ and CSF Aβ42, Tau, or MMSE
scores, which is in line with previous plasma Aβ mono-
mer studies [7, 26, 27, 30]. However, these correlations
were not strong, and an explanation for this could be
the peripheral production of plasma Aβ, by platelets,
skeletal muscle cells, and other cell types [31] that con-
tribute to circulating Aβ levels resulting in a dilution of
the relation with CNS processes.
This is the first study to report on plasma AβOs as a
marker for brain amyloidosis in a large amyloid PET-
confirmed cohort. As the definition of AD is shifting
from a syndrome to a biological construct, it is relevant
Fig. 2 Boxplots present higher levels of plasma MDS-OAβ in abnormal amyloid PET individuals in samples with ≤ 4 years storage (n = 207) (A), and no change
in samples > 4 years storage (n = 192) (B). Scatterplots present the correlation in samples ≤ 4 years storage (n = 207) between plasma MDS-OAβ and CSF
biomarker concentrations: CSF Aβ 42 (C), CSF Tau (D), CSF pTau (E), and the correlation between plasma MDS-OAβ and MMSE score (F). Blue dots represent
normal amyloid PET individuals, and red dots represent abnormal amyloid PET individuals. ***p-value < 0.001
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to evaluate the performance of biomarkers in discrimin-
ating amyloid status [8]. One small-scale study did
evaluate oligomeric assemblies of misfolded Aβ protein
as a plasma marker for amyloid status between pro-
dromal PET-positive individuals (n = 36) and healthy
elderly PET-negative individuals (n = 37) [6]. Using an
immune-infrared sensor method, they achieved an AUC
of 0.78 (95% CI 0.68–0.88) [6]. We showed a similar
good accuracy of plasma MDS-OAβ to screen for amyl-
oid status (AUC, 0.81) in a large amyloid PET-confirmed
cohort when combined with APOEe4 and age. When
restricting the analyses to individuals in pre-dementia
stages (i.e., CN and MCI), the accuracy of plasma MDS-
OAβ combined with APOEe4 and age increased further
to 0.86.
One of the suggested applications of a plasma Aβ bio-
marker is a screening test for brain amyloidosis in spe-
cialized memory clinics or for clinical trial inclusion
[32]. Previous studies have been successful in identifying
amyloid status with high accuracies (AUC, 0.79–0.97)
using various types of plasma Aβ markers [26–30, 33]
and plasma pTau isoforms [34–38]. The plasma MDS-
OAβ assay had similar or somewhat lower accuracies
compared to these other plasma biomarker tests. While
techniques used in some studies, such as
immunoprecipitation mass spectrometry [28, 29], are
labor-intensive and time-consuming, the Simoa assays
and the MDS method allow high-throughput analysis.
The MDS method highly resembles an ELISA in simpli-
city and automation possibilities [7, 18, 39] and as such,
allows broad implementation. Another added value of
our study is that we have tested the plasma MDS-OAβ
assay in a heterogeneous cohort including other neuro-
degenerative or neuropsychiatric disorders besides the
clinical AD spectrum, while previous plasma Aβ in-
cluded primarily cohorts which contained the clinical
AD spectrum (i.e., healthy controls, MCI, or AD demen-
tia). The heterogeneity of the cohort used in this current
study better resembles a memory clinic population, the
setting where plasma biomarkers will likely be applied in
the future to pre-screen for brain amyloidosis. Addition-
ally, using plasma MDS-OAβ as a pre-screener in a
hypothetical clinical trial scenario lowered the number
of PET scans up to 40% depending on clinical diagnosis.
Therefore, plasma MDS-OAβ could be beneficial for
pre-screening in clinical trial settings, as it could poten-
tially reduce costs.
It is well known that pre-analytical factors concerning
sample handling and processing can influence the mea-
sured concentration of (plasma) biomarkers, therefore
Fig. 3 Receiver operating characteristic (ROC) curves discriminate abnormal amyloid from normal amyloid subjects as defined by amyloid PET scan
based on plasma Aβ oligomer levels (blue line), age and APOEe4 genotype (purple line), and a multivariate model including APOEe4 genotype, age,
and plasma Aβ oligomer levels (yellow line)
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leading to variability in results, preventing establishment
of a universal cutoffs and between-laboratory compari-
sons [40, 41]. We previously observed a negative effect
of long-term storage on plasma MDS-OAβ levels upon
visual inspection (data not published) and, therefore, de-
cided to evaluate this in the current study. We found
that for samples with a storage time > 4 years plasma
MDS-OAβ levels no longer differed between normal and
abnormal amyloid individuals. Our finding is not fully in
line with one recent study that investigated the long-
term storage effect on plasma monomeric Aβ and found
stable plasma Aβ levels after long-term storage up to 5
years at – 80 °C [42]. This discrepancy might be caused
by the difference in storage length between the previous
study (up to 5 years) and the current study (up to 19
years). It might also be caused by the difference in ana-
lytical methods (MDS vs. IMR) or the different Aβ spe-
cies (MDS-OAβ vs (in principle) monomeric Aβ42). It
could be the case that plasma MDS-OAβ levels of nor-
mal amyloid increase over time and reach similar levels
as plasma MDS-OAβ levels of abnormal amyloid indi-
viduals, whereas in monomeric Aβ42 this does not hap-
pen. It could be hypothesized that long-term storage
might induce stress on the oligomeric Aβ42 protein
which results in perturbation of the protein and an in-
creased aggregation tendency in normal amyloid individ-
uals, which does not occur in abnormal amyloid
individuals as they have already reached maximum
oligomerization. A similar increase in protein aggrega-
tion induced by protein-stress has previously been re-
ported after freeze-thawing [43]. The effect of long-term
storage time implies that the plasma MDS-OAβ assay
cannot be used to perform research projects with sam-
ples that have been stored in biobanks for a long period.
This novel finding could be of interest to other research
groups interested in measuring plasma biomarkers of
amyloid. Additional pre-analytical testing is needed to
determine the precise maximum storage period and to
compare the effect of long-term storage with other types
of blood-based Aβ biomarkers. Nonetheless, as in daily
clinical routine, fresh blood samples are used; we do not
expect this will present a problem for daily clinical prac-
tice. This is supported by recent results from a system-
atic study into pre-analytical stability, showing no effect
of up to 2 weeks storage at either room temperature or
– 20 °C on the plasma MDS-OAβ levels (manuscript
under review).
Our study has several strengths including our large
well-defined amyloid PET-confirmed memory clinic
population. In addition, CSF and plasma collection fol-
lows a highly standardized protocol in our center, thus
minimizing confounding effects in pre-analytical pro-
cessing. Moreover, the oligomerization assay technique
developed for this plasma MDS-OAβ assay can
potentially be employed for other proteinopathies as
well, such as α-synuclein which is often seen in dementia
with Lewy bodies. This might result in a screening panel
of plasma biomarkers for different types of neurodegen-
erative disease. Among the limitations of our study is
that the plasma MDS-OAβ assay is not yet available on
an automatic platform, thus enhancing the risk for ana-
lytical variation. However, automation is currently under
development, further facilitating broad implementation
and minimizing analytical variation. In addition, plasma
MDS assays for other AD biomarkers, such as phosphor-
ylated Tau, are currently under development to further
capture the full pathological profile of AD [8]. Lastly, it
would be interesting to study the association between
plasma MDS-OAβ with specific cognitive domains,
through elaborate neuropsychological testing, to get an
in-depth understanding of the association between
plasma MDS-OAβ and cognitive impairment.
Conclusions
In conclusion, plasma MDS-OAβ has the potential to be
used as a pre-screener for brain amyloidosis in large het-
erogeneous memory clinic populations. The advantages
of the low-cost MDS-OAβ blood test include the ease of
blood collection over a lumbar puncture or a costly PET
scan. Additionally, using plasma MDS-OAβ as a pre-
screener based on the results of this current study re-
duced the number of amyloid PET scans needed and
lowered total costs up to 40%, highlighting a potential
use for clinical trials settings. In addition, the novel find-
ing of long-term storage duration on plasma MDS-OAβ
levels could be of interest to other research groups inter-
ested in measuring plasma biomarkers of amyloid.
Abbreviations
AD: Alzheimer’s disease; ADC: Amsterdam Dementia Cohort; Amsterdam
UMC: Amsterdam University Medical Centers; APOEe4: Apolipoprotein
epsilon 4; AUC: Area under the curve; Aβ: Amyloid beta; Aβ42: Amyloid Beta
1-42; CSF: Cerebrospinal fluid; CV: Coefficient of variation;
EDTA: Ethylenediamine tetraacetic acid; EEG: Electroencephalography;
ELISA: Enzyme-linked immunosorbent assay; EMIF-AD: The European
Information Framework for AD; GLM: General linear models; MCI: Mild
cognitive impairment; MDS: Multimer detection system; MDS-OAβ: Amyloid
oligomerization tendency measured by the multimer detection platform;
MMSE: Mini Mental State Examination; MRI: Magnetic resonance imaging;
NC: Normal controls; OAβ: Amyloid oligomerization tendency; PET: Positron
emission tomography; pTau: Tau phosphorylated at threonine 181;




RBM designed and conceptualized the study, analyzed the data, interpreted
the data, and was a major contributor in writing the manuscript. PS
interpreted the data and revised the manuscript for intellectual content. SYK
and YCY revised the manuscript for intellectual content. SK performed the
sample analysis and revised the manuscript for intellectual content. SSAA
helped develop the multimer detection system platform and revised the
manuscript for intellectual content. JT helped with the sample selection and
revised the manuscript for intellectual content. BNMB rated all PET scans and
Babapour Mofrad et al. Alzheimer's Research & Therapy          (2021) 13:133 Page 8 of 10
revised the manuscript for intellectual content. PJV provided samples,
interpreted the data, and revised the manuscript for intellectual content.
WMvdF interpreted the data and revised the manuscript for intellectual
content. CET interpreted the data and was a major contributor in writing the




The Alzheimer Center Amsterdam is supported by Stichting Alzheimer
Nederland and Stichting VUmc fonds. Research of the Alzheimer center
Amsterdam is part of the neurodegeneration research program of
Amsterdam Neuroscience. The clinical database structure was developed
with funding from Stichting Dioraphte. The VUmc Biobank is supported by
VUmc. The research leading to these results has received support from the
Innovative Medicines Initiative Joint Undertaking under EMIF grant
agreement no. 115372, resources of which are composed of financial
contribution from the European Union’s Seventh Framework Programme
(FP7/2007-2013) and EFPIA companies’ in kind contribution.
Availability of data and materials
Data are available from the authors upon reasonable request.
Declarations
Ethics approval and consent to participate
The research is in accordance with the ethical consent by the VU University





The authors declare that they have no competing interests. P. Scheltens has
acquired grant support (for the institution) from GE Healthcare, Danone
Research, Piramal, and Merck. In the past 2 years, he has received
consultancy/speaker fees from Lilly, GE Healthcare, Novartis, Sanofi, Nutricia,
Probiodrug, Biogen, Roche, Avraham, and EIP Pharma. Gerald Luscan is a
Pfizer employee. All funding is paid to the institution. B.N.M. van Berckel
received research support from ZonMW, AVID radiopharmaceuticals, CTMM,
and Janssen Pharmaceuticals. He is a trainer for Piramal and GE. He receives
no personal honoraria. P.J. Visser reports non-financial support from GE
Healthcare, other from Eli-Lilly, other from Janssen Pharmaceutical, grants
from Biogen, outside the submitted work.
W.M. van der Flier holds the Pasman chair and performs contract research
for Biogen and has research programs funded by the ZonMW, NWO, EU-FP7,
Alzheimer Nederland, CardioVascular Onderzoek Nederland, Stichting Dior-
aphte, Gieskes-Strijbis Fonds, Boehringer Ingelheim, Piramal Neuroimaging,
Roche BV, Janssen Stellar, and Combinostics. All funding is paid to her institu-
tion. C.E. Teunissen received grants from the European Commission, the
Dutch Research Council (ZonMW), Association of Frontotemporal Dementia/
Alzheimer’s Drug Discovery Foundation, The Weston Brain Institute, and Alz-
heimer Netherlands. She has functioned in advisory boards of Roche, re-
ceived non-financial support in the form of research consumables from
ADxNeurosciences and Euroimmun, and performed contract research or re-
ceived grants from Probiodrug, Biogen, Esai, Toyama, Janssen prevention
center, Boehringer, Axon Neurosciences, EIP farma.
Author details
1Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry,
Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC,
Amsterdam, The Netherlands. 2Alzheimer Center & Department of Neurology
Amsterdam, Neuroscience Campus Amsterdam Neuroscience, VU University
Medical Center, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam,
the Netherlands. 3Department of Neurology, Seoul National University
Bundang Hospital, Seoul National University College of Medicine,
Gyeonggi-do, Republic of Korea. 4Department of Research and Development,
PeopleBio Inc, Seongnam-si, Republic of Korea. 5Department of Neurology,
Chung-Ang University College of Medicine, Seoul, Republic of Korea.
6Department of Bionanotechnology, Gachon University, Incheon, Republic of
Korea. 7Department of Radiology & Nuclear Medicine, Amsterdam
Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam,
The Netherlands. 8Department of Psychiatry & Neuropsychology, School for
Mental Health and Neuroscience, Maastricht University, Maastricht, The
Netherlands. 9Department of Epidemiology and Biostatistics, Amsterdam
UMC, VU University Medical Center, Vrije Universiteit Amsterdam,
Amsterdam, The Netherlands.
Received: 6 December 2020 Accepted: 4 July 2021
References
1. Hayden EY, Teplow DB. Amyloid β-protein oligomers and Alzheimer’s
disease. Alzheimers Res Ther. 2013;5:60 Accessed at: http://alzres.
biomedcentral.com/articles/10.1186/alzrt226.
2. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25
years. EMBO Mol Med. 2016;8:595–608 Accessed at: https://onlinelibrary.
wiley.com/doi/abs/10.15252/emmm.201606210.
3. Cline EN, Bicca MA, Viola KL, Klein WL. The amyloid-β oligomer hypothesis:
beginning of the third decade. J Alzheimers Dis. 2018;64:S567–610.
4. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons
from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol. 2007;8:101–12.
5. Santos AN, Simm A, Holthoff V, Boehm G. A method for the detection of
amyloid-β1-40, amyloid-β1-42and amyloid-β oligomers in blood using
magnetic beads in combination with flow cytometry and its application in
the diagnostics of Alzheimer’s disease. J Alzheimers Dis. 2008;14(2):127–31
Epub 2008.
6. Nabers A, Perna L, Lange J, et al. Amyloid blood biomarker detects Alzheimer’s
disease. EMBO Mol Med. 2018;10 Accessed at: https://onlinelibrary.wiley.com/
doi/abs/10.15252/emmm.201708763. Accessed December 11, 2019.
7. An SSA, Lee B, Yu JS, et al. Dynamic changes of oligomeric amyloid β levels
in plasma induced by spiked synthetic Aβ42. Alzheimers Res Ther. 2017;9:86
Accessed at: http://alzres.biomedcentral.com/articles/10.1186/s13195-017-
0310-6.
8. Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a
biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:
535–62. https://doi.org/10.1016/j.jalz.2018.02.018 Accessed April 16, 2018.
9. van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: performing
research to optimize care. Perry G, Avila J, Tabaton M, Zhu X, editors. J
Alzheimers Dis. 2018;62:1091–1111. Accessed at: http://www.medra.org/
servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-170850. Accessed April
16, 2018.
10. Van Der Flier WM, Pijnenburg YAL, Prins N, et al. Optimizing patient care
and research: the Amsterdam dementia cohort. J Alzheimers Dis. 2014;41(1):
313–27. https://doi.org/10.3233/JAD-132306.
11. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J,
et al. Sensitivity of revised diagnostic criteria for the behavioural variant of
frontotemporal dementia. Brain. 2011;134(9):2456–77. https://doi.org/10.1
093/brain/awr179.
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild
cognitive impairment: clinical characterization and outcome [published
erratum appears in Arch Neurol 1999 Jun;56(6):760]. Arch Neurol. 1999;56(3):
303–8. https://doi.org/10.1001/archneur.56.3.303.
13. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of
dementia with Lewy bodies. Neurology. 2017;89(1):88–100. Accessed at:
http://www.neurology.org/lookup/doi/10.1212/WNL.0000000000004058.
14. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic
criteria for research studies: report of the ninds-airen international
workshop*. Neurology. 43(2):250–60 Epub 1993.
15. Konijnenberg E, Carter SF, ten Kate M, et al. The EMIF-AD PreclinAD study:
study design and baseline cohort overview. Alzheimers Res Ther. 2018;10:75
Accessed at: https://alzres.biomedcentral.com/articles/10.1186/s13195-018-
0406-7.
16. Tijms BM, Willemse EAJ, Zwan MD, et al. Unbiased approach to counteract
upward drift in cerebrospinal fluid amyloid-β 1–42 analysis results. Clin
Chem. 2018;64:576–85 Accessed at: http://www.clinchem.org/lookup/doi/1
0.1373/clinchem.2017.281055.
17. Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ.
Variability in blood-based amyloid-β assays: the need for consensus on pre-
analytical processing. J Alzheimers Dis. 2012;30:323–36 Accessed at: https://
Babapour Mofrad et al. Alzheimer's Research & Therapy          (2021) 13:133 Page 9 of 10
www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-2
012-120058. Accessed January 16, 2020.
18. Youn YC, Kang S, Suh J, et al. Blood amyloid-β oligomerization associated
with neurodegeneration of Alzheimer’s disease. Alzheimers Res Ther. 2019;
11:40 Accessed at: https://alzres.biomedcentral.com/articles/10.1186/s13195-
019-0499-7. Accessed January 14, 2020.
19. Templeton GF. A two-step approach for transforming continuous variables
to normal: Implications and recommendations for IS research. Commun
Assoc Inf Syst. 28 Epub 2011.
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics. 1988;44:837 Accessed at: https://www.
jstor.org/stable/2531595?origin=crossref.
21. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al.
Prevalence of cerebral amyloid pathology in persons without dementia.
JAMA. 2015;313:1924 Accessed at: http://jama.jamanetwork.com/article.a
spx?doi=10.1001/jama.2015.4668. Accessed December 19, 2019.
22. Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, et al.
Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and
demographic information. Alzheimers Dement Diagnosis Assess Dis Monit.
2016;4:76–84 Accessed at: http://doi.wiley.com/10.1016/j.dadm.2016.07.002.
Accessed December 11, 2019.
23. Zhou L, Chan KH, Chu LW, Kwan JSC, Song YQ, Chen LH, et al. Plasma
amyloid-β oligomers level is a biomarker for Alzheimer’s disease diagnosis.
Biochem Biophys Res Commun. 2012;423:697–702 Accessed at: https://
linkinghub.elsevier.com/retrieve/pii/S0006291X1201090X. Accessed
September 30, 2019.
24. Xia W, Yang T, Shankar G, et al. A specific enzyme-linked immunosorbent
assay for measuring beta-amyloid protein oligomers in human plasma and
brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66:190–9
Accessed at: http://www.ncbi.nlm.nih.gov/pubmed/19204155. Accessed
September 30, 2019.
25. Georganopoulou DG, Chang L, Nam J-M, et al. From The Cover:
Nanoparticle-based detection in cerebral spinal fluid of a soluble
pathogenic biomarker for Alzheimer’s disease. Proc Natl Acad Sci. 2005;102:
2273–6 Accessed at: http://www.pnas.org/cgi/doi/10.1073/pnas.0409336102.
26. Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for
the earliest Alzheimer pathological changes. Ann Neurol. 2018;84:648–58
Accessed at: http://www.ncbi.nlm.nih.gov/pubmed/30196548. Accessed
September 30, 2019.
27. Janelidze S, Stomrud E, Palmqvist S, et al. Plasma β-amyloid in Alzheimer’s
disease and vascular disease. Sci Rep. 2016;6:26801 Accessed at: http://www.
nature.com/articles/srep26801.
28. Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T,
et al. Amyloid β concentrations and stable isotope labeling kinetics of
human plasma specific to central nervous system amyloidosis. Alzheimers
Dement. 2017;13(8):841–9. Accessed at: http://doi.wiley.com/10.1016/j.jalz.2
017.06.2266.
29. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High
performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature.
2018;554:249–54 Accessed at: http://www.nature.com/articles/nature25456.
30. Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated
plasma assays as screening tests for alzheimer disease–related β-amyloid
status. JAMA Neurol. 2019;76:1060 Accessed at: https://jamanetwork.com/
journals/jamaneurology/fullarticle/2736342.
31. Roher AE, Esh CL, Kokjohn TA, Castaño EM, van Vickle GD, Kalback WM,
et al. Amyloid beta peptides in human plasma and tissues and their
significance for Alzheimer’s disease. Alzheimers Dement. 2009;5:18–29
Accessed at: http://doi.wiley.com/10.1016/j.jalz.2008.10.004.
32. Zetterberg H. Blood-based biomarkers for Alzheimer’s disease—an update. J
Neurosci. 2019;319:2–6.
33. Verberk IMW, Thijssen E, Koelewijn J, et al. Combination of plasma amyloid
beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with
cerebral amyloid pathology. Alzheimers Res Ther. 2020;12(1):118 Epub 2020.
34. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma
phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar
degeneration. Nat Med. 2020;26(3):387–97 Epub 2020.
35. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer’s
disease: relationship to other biomarkers, differential diagnosis,
neuropathology and longitudinal progression to Alzheimer’s dementia. Nat
Med. 2020;26(3):379–86 Epub 2020.
36. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al.
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs
other neurodegenerative disorders. J Am Med Assoc. 2020;324:772–81
Accessed at: https://jamanetwork.com/journals/jama/fullarticle/2768841.
Accessed September 1, 2020.
37. Ashton NJ, Hye A, Rajkumar AP, et al. An update on blood-based
biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol.
2020;16(5):265–84.
38. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a
biomarker for Alzheimer’s disease: a diagnostic performance and prediction
modelling study using data from four prospective cohorts. Lancet Neurol.
2020;19(5):422–33 Epub 2020.
39. Meng X, Li T, Wang X, et al. Association between increased levels of
amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s
disease. Alzheimers Res Ther. 2019;11:89 Accessed at: https://alzres.
biomedcentral.com/articles/10.1186/s13195-019-0535-7. Accessed January
14, 2020.
40. Hansson O, Mikulskis A, Fagan AM, et al. The impact of preanalytical variables
on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis:
a review. Alzheimers Dement. 2018;14:1313–33 Accessed at: http://doi.wiley.
com/10.1016/j.jalz.2018.05.008. Accessed November 21, 2019.
41. Rózga M, Bittner T, Batrla R, Karl J. Preanalytical sample handling
recommendations for Alzheimer’s disease plasma biomarkers. Alzheimers
Dement Diagnosis Assess Dis Monit. Elsevier Inc; 2019;11:291–300.
42. Chiu M-J, Lue L-F, Sabbagh MN, Chen T-F, Chen HH, Yang S-Y. Long-term
storage effects on stability of Aβ1–40, Aβ1–42, and total Tau proteins in
human plasma samples measured with immunomagnetic reduction assays.
Dement Geriatr Cogn Dis Extra. 2019;9:77–86 Accessed at: https://www.ka
rger.com/Article/FullText/496099. Accessed December 11, 2019.
43. Carpenter JF, Manning MC, Randolph TW. Long-term storage of proteins.
Curr Protoc Protein Sci. 2002;27 Accessed at: https://onlinelibrary.wiley.com/
doi/abs/10.1002/0471140864.ps0406s27. Accessed December 13, 2019.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Babapour Mofrad et al. Alzheimer's Research & Therapy          (2021) 13:133 Page 10 of 10
